Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366130 | 0.87 | GAA (0.55) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL17058834 | 0.85 | GAA (0.68) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL13321137 | 0.85 | GAA (0.68) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL18372228 | 0.83 | GAA (0.66) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL17046879 | 0.79 | MAPT (0.60) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL17046878 | 0.79 | MAPT (0.60) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL6176944 | 0.78 | CCR1 (0.54) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL8090836 | 0.78 | KDM4E (0.68) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL17046863 | 0.76 | GAA (0.57) | GAAMAPK1KDM4ERAB9ALMNA | |
| SCHEMBL18372232 | 0.76 | GAA (0.57) | GAAMAPK1KDM4ERAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017053696-A2 | HALOGENATED QUINOLINE DERIVATIVES AS ANTIMICROBIAL AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2017-03-30 | — | — | WO | disclosed |
| US-9012899-B2 | Electroluminescent metal complexes with nucleophilic carbene ligands | BASF SE (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20130292660-A1 | ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS | BASF SE (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8492749-B2 | Electroluminescent metal complexes with nucleophilic carbene ligands | BASF SE (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20110114922-A1 | Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands | UDC IRELAND LIMITED (IE) | 2011-05-19 | — | — | US | disclosed |
| EP-2080796-A1 | Electroluminescent metal complexes with nucleophilic carbene ligands | Ciba Holding Inc. (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008137128-A2 | METHODS OF TREATING FUNGAL INFECTIONS | NORTHEASTERN UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1841834-A1 | ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006067074-A1 | ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110114922-A1 | Electroluminescent Metal Complexes with Nucleophilic Carbene Ligands | OCIAD1, OCIAD2, C1S | GAA 4544/4885MAPK1 1631/4885KDM4E 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.